The anticoagulant will be made available between August and November 2017 under the
brand name Bevyxxa, according to Portola. Betrixaban will be supplied as 40-and 80-mg …

Objective: To evaluate the efficacy, safety, and clinical implication of betrixaban for
prophylaxis of venous thromboembolism (VTE) in patients with acute medical illness. Data …

Venous thromboembolism is commonly defined as a situation in which blood clot forms in
blood vessels. It has two types Deep vein thrombosis (clot became in leg, groin or arm) and …

Purpose The role of betrixaban in the prevention of venous thromboembolism (VTE) in
acutely medically ill patients and its efficacy and safety profiles are reviewed. Summary …

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary
embolism, is a common and potentially preventable cause of morbidity and mortality …

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the factor
Xa (FXa) inhibitor betrixaban for extended-duration prophylaxis of acute medically ill …

Introduction Betrixaban is a novel direct oral factor Xa inhibitor approved by the Food and
Drug Administration for prophylaxis of venous thromboembolism in adult patients …

Venous thromboembolism (VTE) is a prevalent yet preventable cause of death, particularly
among hospitalized patients. Studies have shown that the risk of VTE remains high for up to …

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary
embolism (PE), remains a preventable cause of morbidity and mortality in hospitalized …

Betrixaban (Bevyxxa) is the fourth orally administered anticoagulant that acts by inhibiting
Factor Xa (FXa) activity, joining rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban …